FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549
-------------	------------

Check this box if no longer subject
Section 16. Form 4 or Form 5
bligations may continue. See
estruction 1(h)

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

**OMB APPROVAL** 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Hack Andrew A. F.				D7	2. Issuer Name and Ticker or Trading Symbol  DYNAVAX TECHNOLOGIES CORP  DVAX ]								**			Owner		
(Last)	(Fir	,	Middle)	3. D	Date of Earliest Transaction (Month/Day/Year)								Offic belov	er (give v)	e title	Othe belo	r (specify v)	
C/O BAIN CAPITAL LIFE SCIENCES INVESTORS					05/27/2020													
200 CLARENDON STREET				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street)													X Form	filed b	y One Re	porting Po	erson	
BOSTON MA 02116												Form filed by More than One Reporting Person						
(City)	(Sta	ate) (Z	Zip)															
		Table	I - Non-Deriva	ative	Secur	rities	Acc	quire	ed, Di	isposed o	f, or E	Benefic	ially Own	ed				
1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Yea			ear) E	2A. Deemed Execution D if any (Month/Day/		Co	Transaction D		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 an 5)			5. Amount of Securities Beneficially Owned Followed Reported	Form: Di		rect Ind Be (I) Ov	Nature of irect neficial mership str. 4)		
							Co	ode	v /	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(,		, , ,	
Common Stock 05/27/2020			0	)		P	o <sup>(1)</sup>		1,000,000	A	\$5	8,525,000		I I I		e otnotes <sup>(2)(3)</sup>		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	ution Date, Transaction of Code (Instr. Deriva			ative ities ired sed	Expiration Date (Month/Day/Year) Secut Under Secut Secut 3 and			le and unt of rities rlying rative rity (Instr.	8. Price of Derivative Security (Instr. 5)			10. Ownersl Form: Direct (E or Indire (I) (Instr.	Beneficial Ownership ct (Instr. 4)		
				Code	Code V (A) (D		(D)	Date Exercisable		Expiration e Date	Title	Amount or Number of Shares						

## **Explanation of Responses:**

- 1. On May 27, 2020, Bain Capital Life Sciences Fund, L.P. ("BCLS") and BCIP Life Sciences Associates, LP ("BCIPLS" and, collectively with BCLS, the "Bain Life Sciences Entities") purchased, in the aggregate, 1,000,000 shares of common stock of the Issuer at a price of \$5.00 per share, pursuant to an underwritten public offering.
- 2. Represents shares of common stock held directly by the Bain Life Sciences Entities.
- 3. Bain Capital Life Sciences Investors, LLC ("BCLSI") is the ultimate general partner of BCLS, and governs the investment strategy and decision-making process with respect to investments held by BCIPLS. Dr. Hack is a Managing Director of BCLSI. By virtue of the relationships described in this footnote, Dr. Hack may be deemed to share voting and dispositive power with respect to the securities held by the Bain Life Sciences Entities. Dr. Hack disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

## Remarks:

/s/ Andrew A.F. Hack 05/28/2020

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.